多巴胺对胶质瘤细胞U251增殖、侵袭及VEGF表达影响
|
摘要
目的探讨多巴胺对胶质瘤细胞U251增殖、侵袭及血管内皮生长因子(VEGF)表达的影响及意义。方法将人胶质瘤细胞株U251分为5组,分别加入多巴胺0(对照)、10、25、50、100μmol/L,分别于培养12、24、36、48 h时,采用细胞计数试剂盒(CCK-8)法检测细胞增殖情况,采用流式细胞仪和Transwell实验检测培养48 h后细胞周期及侵袭能力变化,采用Western blot检测细胞中细胞周期蛋白D1(cyclin D1)、细胞周期蛋白依赖性激酶4(CDK-4)、CDK-6及VEGF、基质金属蛋白酶2(MMP-2)、MMP-9表达。结果与对照组[(92.36±1.37)%]比较,多巴胺培养48 h时,10、25、50和100μmol/L组U251细胞增殖百分比[(46.82±1.17)%、(41.96±1.06)%、(37.52±0.98)%、(30.57±1.11)%]明显下降(P <0.05),呈剂量依赖性(P <0.05);与对照组比较,多巴胺10、25、50和100μmol/L组U251细胞G0/G1期比例明显增多(P <0.05),S期细胞比例明显减少(P <0.05),具有剂量依赖性;与对照组[(1 099.82±33.57)个]比较,多巴胺10、25、50和100μmol/L组U251细胞侵袭数目[分别为(776.52±25.16)、(555.43±22.57)、(442.33±12.03)、(336.82±14.11)个]均明显减少(P <0.05),呈一定剂量依赖性(P <0.05);与对照组比较,多巴胺10、25、50和100μmol/L组U251细胞中cyclin D1、CDK4、CDK6及VEGF、MMP-2、MMP-9蛋白表达量均明显降低(P <0.05)。
Objective To explore effects and significances of dopamine on the proliferation, invasion, and expression of vascular endothelial growth factor(VEGF) in glioma cell line U251. Methods Human glioma cells line U251 were divided into 5 groups administered with dopamine at doses of 0(control), 10, 25, 50, and 100 μmol/L. CCK-8 method was used to detect cell proliferation at 0, 12, 24, 36 and 48 hours of dopamine treatment. Flow cytometry and Transwell assay were used to detect changes of cell cycle and invasive ability 48 hours after dopamine treatment. The expressions of cyclin D1, cyclin dependent kinase 4(CDK-4), cyclin dependent kinase 6(CDK-6), VEGF, matrix metalloproteinase 2(MMP-2), and matrix metalloproteinase 9(MMP-9) were detected with Western blot. Results Compared to the control cells, the U251 cells with48 hours′ treatment of dopamine at doses of 10, 25, 50, and 100 μmol/L showed following significant variations in significant dose-dependent manners: decreased cell proliferation percentage(46.82 ± 1.17%, 41.96 ± 1.06%, 37.52 ± 0.98%, and 30.57 ±1.11% vs. 92.36 ± 1.37%, P < 0.05 for all); increased percentage of cells in G0/G1 phase(P < 0.05 for all); decreased percentage of cells in S phase(P < 0.05 for all); reduced number of invasive cells(776.52 ± 25.16, 555.43 ± 22.57, 442.33 ±12.03, and 336.82 ± 14.11 vs. 1 099.82 ± 33.57, P < 0.05 for all); and decreased intracellular expressions of cyclin D1,CDK4, CDK6, VEGF, MMP-2, and MMP-9(all P < 0.05). Conclusion Dopamine could inhibit the proliferation and invasion of glioma cell line U251 and the effects may be related to the inhibited intracellular expressions of cyclin D1, CDK-4,CDK-6, VEGF, MMP-2, and MMP-9.
Objective To explore effects and significances of dopamine on the proliferation, invasion, and expression of vascular endothelial growth factor(VEGF) in glioma cell line U251. Methods Human glioma cells line U251 were divided into 5 groups administered with dopamine at doses of 0(control), 10, 25, 50, and 100 μmol/L. CCK-8 method was used to detect cell proliferation at 0, 12, 24, 36 and 48 hours of dopamine treatment. Flow cytometry and Transwell assay were used to detect changes of cell cycle and invasive ability 48 hours after dopamine treatment. The expressions of cyclin D1, cyclin dependent kinase 4(CDK-4), cyclin dependent kinase 6(CDK-6), VEGF, matrix metalloproteinase 2(MMP-2), and matrix metalloproteinase 9(MMP-9) were detected with Western blot. Results Compared to the control cells, the U251 cells with48 hours′ treatment of dopamine at doses of 10, 25, 50, and 100 μmol/L showed following significant variations in significant dose-dependent manners: decreased cell proliferation percentage(46.82 ± 1.17%, 41.96 ± 1.06%, 37.52 ± 0.98%, and 30.57 ±1.11% vs. 92.36 ± 1.37%, P < 0.05 for all); increased percentage of cells in G0/G1 phase(P < 0.05 for all); decreased percentage of cells in S phase(P < 0.05 for all); reduced number of invasive cells(776.52 ± 25.16, 555.43 ± 22.57, 442.33 ±12.03, and 336.82 ± 14.11 vs. 1 099.82 ± 33.57, P < 0.05 for all); and decreased intracellular expressions of cyclin D1,CDK4, CDK6, VEGF, MMP-2, and MMP-9(all P < 0.05). Conclusion Dopamine could inhibit the proliferation and invasion of glioma cell line U251 and the effects may be related to the inhibited intracellular expressions of cyclin D1, CDK-4,CDK-6, VEGF, MMP-2, and MMP-9.
引文
[1]郑立影,吕红.脑胶质瘤治疗策略及其研究进展[J].吉林医药学院学报,2016,37(1):50-53.
[2]李丽,余琼,梁伟民.多巴胺能神经系统对睡眠--觉醒和认知的调控作用[J].现代生物医学进展,2014,14(36):7172-7174.
[3]王峰,李志坚,范源媛,等.老年女性精神分裂症患者乳腺癌风险因素及预防措施[J].中国老年学杂志,2014,34(2):572-574.
[4]Roney MSI,Park SK.Antipsychotic dopamine receptor antagonists,cancer,and cancer stem cells[J].Archives of Pharmacal Research,2018,41(4):384-408.
[5]Peters MA,Walenkamp AM,Kema IP,et al.Dopamine and serotonin regulate tumor behavior by affecting angiogenesis[J].Drug Resistance Updates,2014,17(4-6):96-104.
[6]Cavalieri EL,Rogan EG,Zahid M.Critical depurinating DNAadducts:estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson's disease[J].Int J Cancer,2017,141(6):1078-1090.
[7]Kanakis G,Grimelius L,Spathis A,et al.Expression of somatostatin receptors 1-5 and dopamine receptor 2 in lung carcinoids:implications for a therapeutic role[J].Neuroendocrinology,2015,101(3):211-222.
[8]夏妙芸,林绍坚,吴哲褒.多巴胺受体激动剂治疗催乳素腺瘤的停药策略[J].中华医学杂志,2016,96(19):1550-1552.
[9]Lan YL,Wang X,Xing JS,et al.Anti-cancer effects of dopamine in human glioma:involvement of mitochondrial apoptotic and antiinflammatory pathways[J].Oncotarget,2017,8(51):88488-88500.
[10]韩世愈,王娇.细胞周期蛋白在恶性肿瘤中的表达及其在肿瘤治疗中的作用[J].分子诊断与治疗杂志,2013,5(5):357-360.
[11]Hydbring P,Malumbres M,Sicinski P.Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases[J].Nat Rev Mol Cell Biol,2016,17(5):280-292.
[12]孙凤莉,刘岩青,戴殿禄,等.信号传导与转录激活因子3信号传导通路对结肠癌细胞G1~S期的调控[J].中华实验外科杂志,2016,33(8):1985-1987.
[13]Cole SW,Nagaraja AS,Lutgendorf SK,et al.Sympathetic nervous system regulation of the tumour microenvironment[J].Nat Rev Cancer,2015,15(9):563-572.
[14]Harjes U.Tumour angiogenesis:controlling nerves[J].Nature Reviews Cancer,2017,17(12):708.
[15]韩翠翠,杨莹,马立威,等.肿瘤血管生成的分子机制及治疗策略[J].医学研究杂志,2015,44(2):8-11.
[16]Moreno-Smith M,Lee SJ,Lu C,et al.Biologic effects of dopamine on tumor vasculature in ovarian carcinoma[J].Neoplasia,2013,15(5):502-510.
[17]马莉.VEGF及其受体的生物学特性及在肿瘤血管生成中的作用[J].中国优生与遗传杂志,2016,24(5):146-148.
[18]Faraji SN,Mojtahedi Z,Ghalamfarsa G,et al.N-myc downstream regulated gene 2 overexpression reduces matrix metalloproteinase-2 and-9 activities and cell invasion of A549 lung cancer cell line in vitro[J].Iran J Basic Med Sci,2015,18(8):773-779.
[19]马庆防,黎军,王永楠,等.COX-2与MMP-9和VEGF在胶质瘤中的表达及意义[J].中华肿瘤防治杂志,2016,23(s2):24-25.
[20]侯保辉.转染VEGF小干扰RNA的脑胶质瘤细胞U251增殖、侵袭能力变化及其机制[J].山东医药,2017,57(19):29-32.
[2]李丽,余琼,梁伟民.多巴胺能神经系统对睡眠--觉醒和认知的调控作用[J].现代生物医学进展,2014,14(36):7172-7174.
[3]王峰,李志坚,范源媛,等.老年女性精神分裂症患者乳腺癌风险因素及预防措施[J].中国老年学杂志,2014,34(2):572-574.
[4]Roney MSI,Park SK.Antipsychotic dopamine receptor antagonists,cancer,and cancer stem cells[J].Archives of Pharmacal Research,2018,41(4):384-408.
[5]Peters MA,Walenkamp AM,Kema IP,et al.Dopamine and serotonin regulate tumor behavior by affecting angiogenesis[J].Drug Resistance Updates,2014,17(4-6):96-104.
[6]Cavalieri EL,Rogan EG,Zahid M.Critical depurinating DNAadducts:estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson's disease[J].Int J Cancer,2017,141(6):1078-1090.
[7]Kanakis G,Grimelius L,Spathis A,et al.Expression of somatostatin receptors 1-5 and dopamine receptor 2 in lung carcinoids:implications for a therapeutic role[J].Neuroendocrinology,2015,101(3):211-222.
[8]夏妙芸,林绍坚,吴哲褒.多巴胺受体激动剂治疗催乳素腺瘤的停药策略[J].中华医学杂志,2016,96(19):1550-1552.
[9]Lan YL,Wang X,Xing JS,et al.Anti-cancer effects of dopamine in human glioma:involvement of mitochondrial apoptotic and antiinflammatory pathways[J].Oncotarget,2017,8(51):88488-88500.
[10]韩世愈,王娇.细胞周期蛋白在恶性肿瘤中的表达及其在肿瘤治疗中的作用[J].分子诊断与治疗杂志,2013,5(5):357-360.
[11]Hydbring P,Malumbres M,Sicinski P.Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases[J].Nat Rev Mol Cell Biol,2016,17(5):280-292.
[12]孙凤莉,刘岩青,戴殿禄,等.信号传导与转录激活因子3信号传导通路对结肠癌细胞G1~S期的调控[J].中华实验外科杂志,2016,33(8):1985-1987.
[13]Cole SW,Nagaraja AS,Lutgendorf SK,et al.Sympathetic nervous system regulation of the tumour microenvironment[J].Nat Rev Cancer,2015,15(9):563-572.
[14]Harjes U.Tumour angiogenesis:controlling nerves[J].Nature Reviews Cancer,2017,17(12):708.
[15]韩翠翠,杨莹,马立威,等.肿瘤血管生成的分子机制及治疗策略[J].医学研究杂志,2015,44(2):8-11.
[16]Moreno-Smith M,Lee SJ,Lu C,et al.Biologic effects of dopamine on tumor vasculature in ovarian carcinoma[J].Neoplasia,2013,15(5):502-510.
[17]马莉.VEGF及其受体的生物学特性及在肿瘤血管生成中的作用[J].中国优生与遗传杂志,2016,24(5):146-148.
[18]Faraji SN,Mojtahedi Z,Ghalamfarsa G,et al.N-myc downstream regulated gene 2 overexpression reduces matrix metalloproteinase-2 and-9 activities and cell invasion of A549 lung cancer cell line in vitro[J].Iran J Basic Med Sci,2015,18(8):773-779.
[19]马庆防,黎军,王永楠,等.COX-2与MMP-9和VEGF在胶质瘤中的表达及意义[J].中华肿瘤防治杂志,2016,23(s2):24-25.
[20]侯保辉.转染VEGF小干扰RNA的脑胶质瘤细胞U251增殖、侵袭能力变化及其机制[J].山东医药,2017,57(19):29-32.